Revenue Performance - In 2024, the company's operating revenue was 336,380,651.11 yuan, a decrease of 6.74% compared to 2023's 360,689,152.26 yuan, indicating challenges in market expansion and potential market share erosion [1] - The surgical power consumables segment grew steadily, with a year-on-year increase of 15.69%, while the surgical power devices and new product equipment saw revenue declines due to external factors such as delayed bidding [1] - Certain products, like breast biopsy needles, experienced a slight revenue drop due to centralized procurement impacts, although neurosurgery, orthopedics, and ENT consumables showed significant growth exceeding 40% [1] Profitability Analysis - The net profit attributable to shareholders was 98,666,904.12 yuan, down 15.92% from 117,344,082.20 yuan in 2023, influenced by increased R&D expenses and reduced government subsidies [2] - R&D expenses rose to 55,239,983.73 yuan, an 18.79% increase, which compressed profit margins, while government subsidies fell from 14,461,373.20 yuan in 2023 to 4,643,974.74 yuan in 2024 [2] - The non-GAAP net profit decreased by 22.45% to 71,710,314.84 yuan, indicating weakened core business profitability and challenges in enhancing main business earnings [2] Earnings Per Share - Basic earnings per share (EPS) for 2024 was 1.97 yuan, down 22.13% from 2.53 yuan in 2023, directly affecting shareholder returns [3] - The non-GAAP EPS fell by 28.14% to 1.43 yuan, further highlighting the decline in profitability and challenges in operational stability [3] Expense Management - Total expenses remained relatively stable, with sales expenses at 87,641,744.80 yuan, a slight increase of 0.06% from 2023, and management expenses rising by 2.87% to 25,253,817.19 yuan [3] - R&D expenses accounted for 16.42% of operating revenue, up from 12.89% in 2023, reflecting a commitment to innovation despite short-term profit impacts [3] R&D Personnel - The number of R&D personnel increased by 19% to 144, indicating a focus on enhancing R&D capabilities [4] - The educational background of R&D staff includes 7 PhDs, 48 Master's degrees, and 84 Bachelor's degrees, suggesting a need for further optimization to attract high-end talent [4] Cash Flow Analysis - Net cash flow from operating activities decreased by 42.03% to 39,468,869.13 yuan, primarily due to increased expenditures on materials, salaries, taxes, and R&D [5] - Cash flow from investing activities improved significantly to 309,379,187.15 yuan, compared to -1,312,509,545.87 yuan in 2023, indicating effective adjustments in investment strategy [5] - Cash flow from financing activities was -502,774,371.32 yuan, reflecting increased outflows due to share buybacks and dividends, emphasizing a focus on shareholder returns [5]
西山科技2024年报解读：营收净利双降，研发投入与现金流引关注